Assembly Ebit Per Revenue vs Current Deferred Revenue Analysis

ASMB Stock

USD 15.04 0.32 2.17%

Assembly Biosciences financial indicator trend analysis is way more than just evaluating Assembly Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Assembly Biosciences is a good investment. Please check the relationship between Assembly Biosciences Ebit Per Revenue and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.

Ebit Per Revenue vs Current Deferred Revenue

Ebit Per Revenue vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Assembly Biosciences Ebit Per Revenue account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Assembly Biosciences' Ebit Per Revenue and Current Deferred Revenue is -0.18. Overlapping area represents the amount of variation of Ebit Per Revenue that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Assembly Biosciences, assuming nothing else is changed. The correlation between historical values of Assembly Biosciences' Ebit Per Revenue and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit Per Revenue of Assembly Biosciences are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Ebit Per Revenue i.e., Assembly Biosciences' Ebit Per Revenue and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.18

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ebit Per Revenue

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Assembly Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Assembly Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.The current year's Tax Provision is expected to grow to about 34.6 K, whereas Selling General Administrative is forecasted to decline to about 17.7 M.

	2021	2022	2023	2024 (projected)
Interest Income	302K	1.0M	2.4M	1.6M
Net Interest Income	302K	1.0M	2.4M	1.6M

Interest Income Net Interest Income

Assembly Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets
Total Assets		0.09	0.93	0.55	0.95	0.78	-0.46	-0.48	0.16	0.59	0.71	0.72	0.72	0.98	0.41	0.52	-0.4	0.6	0.68	0.56	0.78	0.98	0.37	0.51	0.42	0.96
Short Long Term Debt Total	0.09		-0.12	-0.66	0.27	-0.13	-0.31	0.74	0.2	0.16	0.49	0.13	0.16	0.0	-0.72	0.08	0.27	-0.37	-0.6	-0.48	-0.13	-0.01	0.11	0.01	-0.26	-0.08
Other Current Liab	0.93	-0.12		0.65	0.87	0.82	-0.44	-0.63	0.25	0.58	0.53	0.73	0.73	0.95	0.53	0.49	-0.39	0.68	0.78	0.58	0.82	0.96	0.44	0.58	0.41	0.93
Total Current Liabilities	0.55	-0.66	0.65		0.3	0.5	-0.04	-0.87	-0.26	0.24	-0.02	0.31	0.27	0.61	0.86	0.11	-0.32	0.53	0.87	0.94	0.51	0.62	-0.07	0.05	0.27	0.61
Total Stockholder Equity	0.95	0.27	0.87	0.3		0.77	-0.5	-0.31	0.31	0.59	0.79	0.76	0.77	0.92	0.23	0.6	-0.34	0.58	0.52	0.29	0.77	0.92	0.53	0.64	0.45	0.91
Property Plant And Equipment Net	0.78	-0.13	0.82	0.5	0.77		-0.22	-0.52	0.16	0.42	0.41	0.61	0.6	0.8	0.47	0.37	-0.26	0.75	0.66	0.37	1.0	0.8	0.46	0.58	0.54	0.84
Net Debt	-0.46	-0.31	-0.44	-0.04	-0.5	-0.22		0.16	-0.13	-0.96	-0.45	-0.31	-0.33	-0.43	-0.14	-0.43	0.08	-0.22	-0.26	-0.09	-0.22	-0.43	-0.6	-0.57	-0.2	-0.4
Retained Earnings	-0.48	0.74	-0.63	-0.87	-0.31	-0.52	0.16		0.26	-0.33	0.02	-0.25	-0.22	-0.55	-0.98	-0.26	0.38	-0.67	-0.97	-0.71	-0.53	-0.55	-0.29	-0.41	-0.49	-0.56
Accounts Payable	0.16	0.2	0.25	-0.26	0.31	0.16	-0.13	0.26		0.12	0.14	0.61	0.63	0.17	-0.33	0.43	-0.08	0.25	-0.16	-0.37	0.16	0.18	0.37	0.35	0.09	0.23
Cash	0.59	0.16	0.58	0.24	0.59	0.42	-0.96	-0.33	0.12		0.46	0.41	0.41	0.56	0.3	0.46	-0.16	0.37	0.44	0.26	0.41	0.56	0.6	0.6	0.31	0.57
Non Current Assets Total	0.71	0.49	0.53	-0.02	0.79	0.41	-0.45	0.02	0.14	0.46		0.51	0.54	0.57	-0.1	0.58	-0.44	0.28	0.18	0.1	0.4	0.56	0.35	0.35	0.23	0.56
Non Currrent Assets Other	0.72	0.13	0.73	0.31	0.76	0.61	-0.31	-0.25	0.61	0.41	0.51		1.0	0.71	0.18	0.68	-0.21	0.67	0.41	0.22	0.6	0.71	0.51	0.42	0.3	0.72
Other Assets	0.72	0.16	0.73	0.27	0.77	0.6	-0.33	-0.22	0.63	0.41	0.54	1.0		0.71	0.14	0.7	-0.21	0.66	0.39	0.18	0.6	0.71	0.53	0.44	0.3	0.72
Cash And Short Term Investments	0.98	0.0	0.95	0.61	0.92	0.8	-0.43	-0.55	0.17	0.56	0.57	0.71	0.71		0.48	0.46	-0.34	0.62	0.72	0.61	0.8	1.0	0.35	0.51	0.42	0.97
Common Stock Total Equity	0.41	-0.72	0.53	0.86	0.23	0.47	-0.14	-0.98	-0.33	0.3	-0.1	0.18	0.14	0.48		0.23	-0.31	0.64	0.94	0.69	0.47	0.49	0.26	0.37	0.5	0.5
Common Stock Shares Outstanding	0.52	0.08	0.49	0.11	0.6	0.37	-0.43	-0.26	0.43	0.46	0.58	0.68	0.7	0.46	0.23		-0.31	0.74	0.38	0.02	0.36	0.46	0.64	0.57	0.71	0.55
Non Current Liabilities Total	-0.4	0.27	-0.39	-0.32	-0.34	-0.26	0.08	0.38	-0.08	-0.16	-0.44	-0.21	-0.21	-0.34	-0.31	-0.31		-0.29	-0.42	-0.34	-0.26	-0.34	-0.08	-0.24	-0.23	-0.37
Other Current Assets	0.6	-0.37	0.68	0.53	0.58	0.75	-0.22	-0.67	0.25	0.37	0.28	0.67	0.66	0.62	0.64	0.74	-0.29		0.74	0.3	0.76	0.63	0.61	0.61	0.8	0.71
Other Stockholder Equity	0.68	-0.6	0.78	0.87	0.52	0.66	-0.26	-0.97	-0.16	0.44	0.18	0.41	0.39	0.72	0.94	0.38	-0.42	0.74		0.73	0.67	0.73	0.37	0.5	0.54	0.73
Total Liab	0.56	-0.48	0.58	0.94	0.29	0.37	-0.09	-0.71	-0.37	0.26	0.1	0.22	0.18	0.61	0.69	0.02	-0.34	0.3	0.73		0.37	0.6	-0.28	-0.13	0.13	0.57
Property Plant And Equipment Gross	0.78	-0.13	0.82	0.51	0.77	1.0	-0.22	-0.53	0.16	0.41	0.4	0.6	0.6	0.8	0.47	0.36	-0.26	0.76	0.67	0.37		0.8	0.46	0.57	0.54	0.84
Total Current Assets	0.98	-0.01	0.96	0.62	0.92	0.8	-0.43	-0.55	0.18	0.56	0.56	0.71	0.71	1.0	0.49	0.46	-0.34	0.63	0.73	0.6	0.8		0.36	0.52	0.43	0.97
Short Term Debt	0.37	0.11	0.44	-0.07	0.53	0.46	-0.6	-0.29	0.37	0.6	0.35	0.51	0.53	0.35	0.26	0.64	-0.08	0.61	0.37	-0.28	0.46	0.36		0.9	0.49	0.38
Common Stock	0.51	0.01	0.58	0.05	0.64	0.58	-0.57	-0.41	0.35	0.6	0.35	0.42	0.44	0.51	0.37	0.57	-0.24	0.61	0.5	-0.13	0.57	0.52	0.9		0.61	0.56
Property Plant Equipment	0.42	-0.26	0.41	0.27	0.45	0.54	-0.2	-0.49	0.09	0.31	0.23	0.3	0.3	0.42	0.5	0.71	-0.23	0.8	0.54	0.13	0.54	0.43	0.49	0.61		0.56
Net Tangible Assets	0.96	-0.08	0.93	0.61	0.91	0.84	-0.4	-0.56	0.23	0.57	0.56	0.72	0.72	0.97	0.5	0.55	-0.37	0.71	0.73	0.57	0.84	0.97	0.38	0.56	0.56

Click cells to compare fundamentals

Assembly Biosciences Account Relationship Matchups

Assembly Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	339.9M	283.3M	191.1M	101.8M	137.5M	130.2M
Other Current Liab	13.1M	13.0M	7.1M	7.1M	6.6M	5.0M
Total Current Liabilities	24.4M	24.4M	16.1M	16.3M	39.2M	41.2M
Total Stockholder Equity	273.2M	240.6M	168.9M	82.7M	41.1M	39.0M
Property Plant And Equipment Net	13.8M	10.7M	7.2M	3.9M	2.7M	3.0M
Net Debt	(34.5M)	(49.3M)	(39.2M)	(49.0M)	(17.5M)	(18.4M)
Retained Earnings	(439.4M)	(501.6M)	(631.4M)	(724.5M)	(785.7M)	(746.5M)
Accounts Payable	1.7M	4.6M	2.7M	2.5M	461K	438.0K
Cash	46.7M	59.4M	45.6M	52.4M	19.8M	36.5M
Non Current Assets Total	57.1M	58.8M	36.9M	4.8M	3.7M	3.5M
Non Currrent Assets Other	1.7M	6.4M	1.7M	78K	312.0K	296.4K
Other Assets	1.7M	6.4M	1.7M	1.0	1.15	1.09
Cash And Short Term Investments	274.0M	216.4M	146.6M	91.6M	130.2M	99.4M
Common Stock Total Equity	25K	32K	34K	49K	56.4K	59.2K
Common Stock Shares Outstanding	2.2M	39.7M	46.8M	4.0M	4.6M	4.3M
Liabilities And Stockholders Equity	339.9M	283.3M	191.1M	101.8M	137.5M	130.2M
Non Current Liabilities Total	42.3M	18.2M	6.1M	2.8M	57.1M	62.5M
Other Current Assets	5.4M	13.7M	14.5M	4.4M	6.7M	3.4M
Other Stockholder Equity	712.8M	742.4M	800.7M	807.9M	826.9M	868.3M
Total Liab	66.7M	42.7M	22.1M	19.1M	96.4M	101.2M
Property Plant And Equipment Gross	13.8M	10.7M	7.2M	3.9M	2.9M	3.0M
Total Current Assets	282.8M	224.5M	154.2M	97.0M	133.8M	102.4M
Accumulated Other Comprehensive Income	(201K)	(270K)	(419K)	(803K)	(81K)	(85.1K)
Common Stock	32K	34K	48K	49K	5K	4.8K
Property Plant Equipment	1.8M	1.6M	7.2M	743K	854.5K	1.0M
Net Tangible Assets	231.6M	198.9M	168.9M	82.7M	95.1M	107.5M
Retained Earnings Total Equity	(341.8M)	(439.4M)	(501.6M)	(724.5M)	(652.1M)	(619.5M)
Short Term Investments	227.3M	157.0M	101M	39.2M	110.4M	77.4M
Capital Surpluse	552.8M	712.8M	742.4M	807.9M	929.1M	975.6M
Other Liab	38.9M	33.2M	11.5M	2.7M	2.5M	2.3M
Current Deferred Revenue	5.1M	6.4M	9.0M	2.7M	30.9M	32.5M
Net Receivables	3.4M	1.2M	336K	944K	43K	40.9K
Net Invested Capital	273.2M	240.6M	168.9M	82.7M	41.1M	39.0M
Net Working Capital	258.3M	200.1M	138.1M	80.7M	94.6M	124.0M
Capital Stock	32K	34K	48K	49K	5K	4.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:

How To Invest In Assembly

Details

Is Assembly Stock a good investment?

Details

What is Assembly Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.89)

Revenue Per Share

4.125

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.35)

Return On Equity

(1.02)

The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Assembly Ebit Per Revenue vs Current Deferred Revenue Analysis

Ebit Per Revenue vs Current Deferred Revenue

Ebit Per Revenue vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Ebit Per Revenue

Current Deferred Revenue

Assembly Biosciences fundamental ratios Correlations

Assembly Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Assembly Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Other Assets	+ 1.0	Non Currrent Assets Other
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets
Net Tangible Assets	+ 0.97	Cash And Short Term Investments

Common Stock Total Equity	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Cash	- 0.96	Net Debt
Retained Earnings	- 0.87	Total Current Liabilities
Common Stock Total Equity	- 0.72	Short Long Term Debt Total
Total Liab	- 0.71	Retained Earnings